Other Product Information If youve been overwhelmed by the number of weight-loss medications now available and wonder if these drugs might help you, youll want to get your hands on this new Special Health Report from the experts at Harvard Medical School
It is a triple receptor agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
Self-pay for GLP-1s Many insurance plans will no longer cover GLP-1 medications for weight loss
Effective strategies promote long-term success with weight loss or diabetes care
The FDA approved liraglutide (Victoza) at doses of 0.6 mg, 1.2 mg, and 1.8 mg daily for T2DM patients with unsatisfactory diet or exercise control, and 2.4 mg and 3 mg as a chronic weight management drug
The half-life is approximately six days, supporting once-weekly subcutaneous dosing at target doses of 4, 8, and 12 mg